Aptose Biosciences (TSE:APS) Share Price Passes Above 50 Day Moving Average – Time to Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$2.18 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 100 shares trading hands.

Analyst Ratings Changes

Separately, Alliance Global Partners cut Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold”.

Aptose Biosciences Trading Down 0.4%

The company’s 50 day moving average price is C$2.18 and its two-hundred day moving average price is C$1.94. The firm has a market cap of C$5.74 million, a PE ratio of 3.26 and a beta of -1.05. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) EPS for the quarter. As a group, sell-side analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.